CSF3 and acute myeloid leukemia: An early exploratory study showed that the remission rate of homoharringtonine combined with cytarabine regimen was 22.7% for R/R AML patients [14], and a meta-analysis revealed that the CR rate of homoharringtonine combined with cytarabine plus granulocyte colony-stimulating factor (G-CSF) was around 50% [15].